CJC-1295
Modified GRF (1-29) without DAC (“Mod GRF”) · with DAC variant
GHRH analogue that raises GH and IGF-1; the DAC version had human phase 1/2 data before development stopped.
Not FDA-approved. Not approved. WADA-prohibited. FDA Category 2 bulk listing. This page describes research and public discussion; it is not a recommendation to use.
Overview
CJC-1295 with DAC (drug affinity complex) binds albumin and has a half-life of ~6–8 days; it raised IGF-1 for up to two weeks in healthy adults. The ‘No DAC’ version (Mod GRF 1-29) is short-acting and has no published human trials. Development by ConjuChem ended after a trial participant death (judged unrelated).
Mechanism of action
Binds pituitary GHRH receptors, increasing GH pulse amplitude and downstream IGF-1.
Benefits & evidence ratings
Dosing
Doses show what has been studied or discussed — not guidance. Always follow your prescriber.
| Source | Dose | Frequency | Duration | Route |
|---|---|---|---|---|
Phase 1 (with DAC, Teichman 2006) B Human clinical data | 30–60 mcg/kg | Single or weekly/biweekly doses | Up to ~4 weeks | Subcutaneous |
Online protocols (No DAC) D Anecdotal / community | ~100 mcg | 1–3× daily, often with ipamorelin | 8–12 weeks | Subcutaneous |
Clinical trials & studies
- Phase 12006Prolonged stimulation of GH and IGF-I secretion by CJC-1295 (JCEM)
Healthy adults; IGF-1 elevated 1.5–3× for 9–11 days after single dose.
Safety
Side effects
- Injection-site reactions, flushing
- Water retention, headache
- Possible insulin resistance with sustained GH
Contraindications
- Active cancer
- Diabetic retinopathy
- Pregnancy
Interactions
- Glucocorticoids may blunt response
- Insulin/diabetes drugs
Long-term safety
Unknown; sustained IGF-1 elevation carries theoretical neoplasia risk.
Regulatory status
Unapproved / research
Not approved. WADA-prohibited. FDA Category 2 bulk listing.
FAQ
Commonly discussed alongside
Listing a combination does not mean it has been studied or is safe.